Total for the last 12 months
number of access : ?
number of downloads : ?
ID 116819
Author
Iwatsuki, N Sakamoto Hospital
Bando, Hiroshi Sakamoto Hospital|Tokushima University KAKEN Search Researchers
Okada, M Sakamoto Hospital
Keywords
Oral hypoglycemic agents (OHAs)
Imeglimin
type 2 diabetes mellitus (T2DM)
Glucose-stimulated insulin secretion (GSIS)
Treatment-emergent adverse events (TEAEs)
American Diabetes Association (ADA)
Content Type
Journal Article
Description
Latest Standards of Medical Care in Diabetes was presented in January 2022. Among oral hypoglycemic agents (OHAs), imeglimin has been topic for a novel agent for type 2 diabetes mellitus (T2DM). Pharmacologically, imeglimin is a cyclic molecule including triazine ring. It has both pharmacological mechanism of increased insulin action and elevation of glucose-stimulated insulin secretion (GSIS). Clinically, it showed HbA1c reduction for 0.46% by monotherapy and 0.56-0.92% by combined therapy with other OHAs. From compared administration of 500mg, 1000mg and 1500mg, 1000mg twice doses would be adequate. No remarkable treatment-emergent adverse events (TEAEs) were found for treatment of imeglimin.
Journal Title
SunText Review of Pharmaceutical Sciences
ISSN
27665232
Publisher
SunText Reviews
Volume
3
Issue
1
Start Page
113
Published Date
2022-01-23
Rights
This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
DOI (Published Version)
URL ( Publisher's Version )
FullText File
language
eng
TextVersion
Publisher
departments
Medical Sciences